Dr. Havens has over 30 years clinical experience treating children, adolescents and young adults with HIV infection. In the early 1990’s, Dr. Haven’s co-founded the Wisconsin HIV Primary Care Network, established to assure that care and treatment would be available for women and their children with HIV and AIDS throughout Wisconsin. He has served as Chair of the American Academy of Pediatrics Committee on Pediatric AIDS (2004–2008) and currently serve as Co-Chair of the Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children (responsible for writing the HRSA/NIH “Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection”). This provides Dr. Havens with a broad perspective on issues related to care of youth with HIV in the US.
He has served as a consultant and lecturer on issues related to HIV in children and adolescents in Russia, Kenya, Zambia and for the World Health Organization. Dr. Havens participated as a principal investigator on local and regional studies of HIV in pregnant women and children and on national multicenter trials through the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) group and currently with the Adolescent Trials Network (ATN).
Dr. Havens is honored to be able to write guidelines and participate in research studies, but feels especially lucky to have the opportunity for continued active involvement in patient care so he can continue to learn from patients and their families about the reality and challenges of living with HIV.
Dr. Havens main focus of current research is in the area of HIV treatment and its complications. He is a member of the NIH/NICHD-funded Adolescent Trials Network for HIV/AIDS Intervention, serving on the Adolescent Medicine Leadership group and the Therapeutic Leadership group. He is currently protocol chair on a study of the metabolic consequences of treatment with tenofovir disoproxil fumarate in high risk youth without HIV, and protocol chair of a randomized intervention study in youth with HIV being treated with tenofovir to measure the effect of vitamin D supplementation on bone density. He has also been protocol chair for IMPAACT and ATN studies of pharmacokinetics of antiretrovirals in children and youth. He maintains an interest in study design, and works with Fellows and Faculty at MCW on a variety of studies in other areas.